TRIM2 and cancer: Given that TRIM2 has no effect on physiological ischemia-driven angiogenesis, targeted TRIM2 inhibition could prove therapeutically useful for diseases driven predominantly by pathological angiogenesis including atherosclerosis and cancer, without the adverse effects of inhibiting physiological angiogenesis.